J&J prostate cancer drug shows promising tumor responses in early trial
J&J prostate cancer drug shows promising tumor responses in early trial
Not thousands of headlines. The few lines that move price. For traders: straight from the source, clear and simple.
J&J prostate cancer drug shows promising tumor responses in early trial
Ibotta CTO Luke Swanson sells $1.25 million in company stock
City Holding Co director Robert D. Fisher buys $23,451 in company stock.
City Holding Co director Diane Strong-Treister buys $17,055 in stock
City Holding Co. director James Hoyer buys $14,213 in common stock
Typhoon Champi sweeps past Taiwan, leaving 1 dead, 500 injured
Johnson & Johnson’s prostate cancer drug shrinks tumors in early-stage trial
Swiss stocks outperform Europe as investors retreat from AI trade - Bloomberg
Slide Insurance CRO Matthew Larson sells $307,182 in shares
US Innovation Foundation director sells $1.6M Linkhome shares privately
Asana CEO Daniel Rogers sells $226,596 of ASAN shares
UK to inject £20.4 billion into state-backed lenders in budget, FT reports
Winmark COO Renae Gaudette sells $531,519 in stock
Martine Rothblatt, United Therapeutics CEO, sells $5.5M in stock
Robinhood director Baiju Bhatt sells $5.16M HOOD shares
Peoples Bancorp evp Hugh Donlon sells $101,012 in shares
France’s luxury stores board up windows ahead of fresh protests
UK budget to prioritise bond markets as Labour tensions mount, Bloomberg reports
Zymeworks reports trial results for ovarian cancer drug ZW191
US embassy says security ramped up in Jordan after deadly church attack
News text belongs to its source; only the headline and a short summary appear here.